# Semax: Research Overview — Deep Dive Peptides > A literature summary of Semax, a synthetic ACTH(4-7) analog studied for neuroprotection, BDNF upregulation, and cognitive performance in rodent models. Covers mechanism, findings, community signals and regulatory status. A synthetic stabilized ACTH fragment whose rodent research ties neuroprotection and cognitive sharpening to rapid, region-specific changes in brain growth-factor expression. ## The short version Semax is a synthetic heptapeptide — seven amino acids — derived from the fragment of adrenocorticotropic hormone known as ACTH(4-7), extended at the C-terminal end with a Pro-Gly-Pro tail to slow enzymatic degradation. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro. In rodent experiments, a single intranasal dose produces a fast, region-specific rise in the neurotrophins BDNF and NGF in the brain — the proteins most associated with nerve-cell survival, plasticity, and memory [3][4]. In cerebral ischemia models, it cuts the volume of the infarct and preserves memory [5], and genome-wide analysis frames its neuroprotection as an immunomodulatory and vascular-gene shift rather than a single receptor event [2]. Here is the honest boundary. The overwhelming majority of this research is in rats and mice, from a relatively small set of Russian institutions over three decades. Semax is approved as a prescription drug only in Russia and Ukraine — for stroke, TIA, and cognitive impairment — and has no FDA or EMA approval. In the US it is classified as an unscheduled research chemical. This page describes what was studied; it does not advise on use and lists no human dose. ## What it is Semax is catalogued by its one-letter sequence as MEHFPGP and also by its formal name Met-ACTH(4-7)-Pro-Gly-Pro, reflecting its two-part design: the ACTH(4-7) tetrapeptide core (Met-Glu-His-Phe) linked to a C-terminal Pro-Gly-Pro tripeptide borrowed from the naturally occurring matrix peptide PGP, which slows breakdown by serum peptidases. The parent ACTH fragment has the interesting property of carrying the cognitive and adaptive aspects of the full ACTH hormone *without* the steroidogenic effect — it does not cause cortisol release. The acetate salt form is the most common supplier presentation. Despite structural kinship with ACTH, Semax is not a hormone replacement and does not act on the adrenal axis in the way full-length ACTH does. It is a synthetic research peptide with no approved drug status in Western countries. ## How it works Two main mechanisms run through the Semax literature, with a third concerning its rapid brain penetration. *Neurotrophin upregulation.* A single 50 micrograms-per-kilogram intranasal dose in male Wistar rats changed NGF and BDNF gene expression rapidly and in a region-specific pattern: NGF and BDNF mRNA rose in the hippocampus, BDNF rose in brainstem and cerebellum, while NGF mRNA fell in frontal cortex — the same dose, opposite directions depending on brain region [3]. At the protein level, intranasal Semax at 50 and 250 micrograms per kilogram specifically increased BDNF protein in rat basal forebrain within 3 hours, but not in cerebellum [4]. A specific, reversible, calcium-dependent binding site in rat brain membranes and astrocyte cultures has been characterized, with a dissociation constant of 2.4 nM and a Bmax of 33.5 fmol per milligram protein [4]. *Enkephalinase inhibition.* In human serum in vitro, Semax inhibited the enzymes that degrade the body's own enkephalin peptides (neprilysin-type enzymes) with an IC50 of roughly 10 micromolar — more potently than several reference inhibitors [7]. Slowing enkephalin breakdown prolongs the signaling of endogenous opioid-peptide pathways linked to mood and stress response. *Neuroprotection via immunomodulation.* Genome-wide transcriptional analysis after permanent middle cerebral artery occlusion in rats showed that Semax predominantly altered immune-system genes (immunoglobulins and chemokines accounted for over 50% of affected genes) and vascular-system genes, framing the neuroprotective effect as a coordinated immunomodulatory and vascular shift rather than a simple single-target action [2]. *Brain penetration.* After a 50-microgram-per-kilogram intranasal dose in rats, about 0.093% of the radioactivity per gram appeared in brain within 2 minutes, with roughly 80% arriving as intact Semax and the remainder as metabolites; the intact peptide was then rapidly degraded enzymatically [6]. ## What the research shows *Neuroprotection and memory in ischemia.* Six days of intranasal Semax in a rat model of focal photoinduced prefrontal-cortex ischemia decreased the volume of the cortical infarction and improved retention of a conditioned passive-avoidance response — an antiamnesic effect — versus untreated controls [5]. *Genome-wide immune and vascular mechanism.* In rats after permanent middle cerebral artery occlusion, Semax's most prominent transcriptional effect was on immune genes (>50% of gene changes at 3 and 24 hours) and on 24 vascular-system genes at 3 hours and 12 at 24 hours, establishing that the neuroprotection is not a simple single-pathway story [2]. *BDNF and NGF: gene expression.* Region-specific changes in neurotrophin mRNA in male Wistar rats after a single dose illustrate the precision and non-uniformity of the effect: the same peptide at the same dose both raised and lowered different neurotrophin transcripts depending on brain region [3]. *BDNF protein and binding site.* Dose-dependent BDNF protein increase in rat basal forebrain at 3 hours, with a pharmacologically characterized high-affinity binding site, places Semax's neurotrophic mechanism on firmer molecular ground than many nootropic compounds [4]. *Spinal-cord injury, 2025.* In female C57BL/6 mice with T9–T10 spinal cord injury, Semax improved locomotor recovery and inhibited a form of programmed cell death (pyroptosis), acting on the mu-opioid-receptor gene Oprm1 through a USP18/FTO deubiquitination axis [1]. This is a different model from cognitive research but extends the neuroprotective evidence to a 2025 publication. *Human context.* Almost all clinical experience comes from Russian and Ukrainian medical practice and Russian-language literature, in indications including ischemic stroke, TIA, optic-nerve disease, and cognitive impairment. There are no published Western randomized controlled trials. ## Reported effects, cautions & safety The following community-reported effects are anecdotal, not clinical evidence. They are drawn from nootropics forums, peptide-user community guides, and biohacker writeups, and they are presented here because they are part of the honest record of how this compound is actually used and experienced — separate from what the cited studies established. **What users commonly describe (anecdotal, not clinical evidence):** The most consistent report is a rapid sense of mental clarity — organized thinking, mental fog lifting — without the wired quality of stimulants. Sustained focus and task-completion drive are very commonly noted alongside stimulant-free motivation. Some describe improved verbal fluency and word recall. A modest mood lift and stress resilience, described as steadying rather than euphoric, is frequently mentioned. A notable minority report little to no effect; the experience is often described as subtle and only obvious in retrospect. On the adverse side: afternoon fatigue or sleepiness as the effect fades; irritability and overstimulation especially when combined with stimulants; occasional headache; nasal irritation, burning, or congestion from the intranasal route (commonly described as fading within 10–15 minutes); vivid dreams or disrupted sleep when taken late in the day; apparent tolerance prompting some users to cycle. **Cited safety cautions:** - *Unregulated supply.* In the US and most Western countries Semax is sold as a research chemical with no required identity, purity, sterility, or dosing verification. - *Limited long-term human safety data.* Almost all human experience is from Russian/Ukrainian clinical practice in structured medical settings; long-term nootropic use in healthy people is uncharacterized in independent literature. - *Intranasal mucosal irritation.* Repeated application of research-grade solutions carries irritation risk; sterility and pH are not controlled outside a pharmacy. - *Unknown drug interactions.* In rodent studies, Semax strongly potentiated amphetamine-evoked dopamine release and raised serotonin metabolite levels [7]; combining it with stimulants, serotonergic drugs, or opioid-active medications has unstudied and potentially additive effects. - *Neurotrophin and gene-expression scope.* Rapidly shifting BDNF, NGF, and large numbers of immune and vascular genes is not a trivial tweak to brain signaling; the consequences of repeatedly driving these changes in a healthy human brain over months are not studied [3][2]. - *No established human dosing framework.* All quantitative data are from rodent studies expressed per kilogram body weight; there is no validated human dose schedule outside Russian clinical formulations. ![Semax neural connectivity and synaptic signaling in cold slate and ice blue](/images/semax.webp) ## Where it fits in cognitive research Among the two peptides on this desk, Semax is the lead: it is more broadly studied, has a mechanistically richer literature, and its neuroprotective and neurotrophic effects are documented at both the gene-expression and protein levels [3][4]. Yet its human evidence base remains tightly concentrated in Russian-language clinical literature with no independent Western RCTs. Read alongside [Selank](/selank), which approaches cognition through the anxiety-reduction side, Semax illustrates a different entry point — a compound that may sharpen focus by upregulating the brain's growth-factor signaling rather than by quieting inhibitory anxiety. See how they line up on the [comparison page](/compare). --- Peer-reviewed research, carefully read — a literature digest, not a clinic or a vendor, and never a dose.